- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02768818
Modulation of the Intestinal Flora With the Probiotic VIVOMIXX™ in Pregnant Women at Risk of Metabolic Complications
The investigators aimed at evaluating the effectiveness of probiotics ingestion in changing maternal microbiota and preventing gestational diabetes in overweight and obese women.
To achieve these goals, obese (BMI> 30 kg/m^2) or overweight (BMI> 25 kg/m^2) pregnant women with risk factors were enrolled in the study and randomized to the supplementation with the probiotic VIVOMIXX® or with placebo.
The endpoints of this study are to evaluate if the dietary supplementation with the probiotic VIVOMIXX® modifies the maternal fecal microbiota (bifidobacteria and lactobacilli) and related enzymatic activity (alkaline sphingomyelinase and alkaline phosphatase), and if this if this is linked to an improvement of the intermediate metabolism (positive Oral Glucose Tolerance Test at 24-26 weeks).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, randomized, double-blind, placebo-controlled trial.
208 pregnant women from the recruiting centers will be enrolled as follow: Women eligible to participate, prior informed consent, will be randomized to 2 capsules twice daily before breakfast and before dinner from randomization until delivery. The boxes will be given to the patients coded and blinded to investigators and participants, and will contain either the active ingredient (VIVOMIXX®, a mixture of 112 billion of eight strains for each capsule, namely Streptococcus thermophilus, bifidobacteria (B. breve, B. longum, B. infantis) and lactobacilli (L. paracasei, L. acidophilus, L. delbrueckii subsp bulgaricus, L. plantarum) or placebo.
The protocol includes a screening visit (Visit 1) at 10-12 weeks, two visits during pregnancy (at 26-28 weeks= Visit 2, and at 36-38 weeks=Visit 3) and a postnatal visit (2-3 days after delivery=Visit 4).
Eligible women should take two capsules twice daily (2 in the morning and 2 in the evening). Patients will be randomly assigned to the control or the VIVOMIXX® group.
The study agent VIVOMIXX® as well as the placebo will be supplied by "Mendes SA" for the whole study period.
During Visit 1 (at 10-12 weeks) written consent will be obtained, after information on expected benefits and possible inconveniences related to participation in the trial. Furthermore, eligible women will be asked to complete two questionnaires, one on dietary habits and one on gastrointestinal symptoms. The questionnaire on gastrointestinal symptoms will be submitted to the patients at each visit.
Height will be assessed at Visit 1, while the following parameters will be measured at each visit: weight, waits/hip circumference ratio, arterial blood pressure, plasma hemoglobin (Hb), hematocrit (Ht), fasting glycemia, fasting insulin and fasting glycated hemoglobin (HbA1c1).
A blood sample for the evaluation of homocysteine will be taken as well as urine and a faeces sample will be collected for nuclear-magnetic-resonance (NMR)-based metabolomics and intestinal microbiota analysis.
Furthermore, an Arm-band will be positioned for monitoring sleep and physical activities for one week at each visit.
At Visit 2 and 3 data regarding ultrasound examinations (Amniotic fluid index, abdominal circumference, cephalic circumference ratio) will be also collected.
Two-three days after delivery (Visit 4) data regarding the delivery (mode of delivery, gestational age at delivery) as well as the newborn (Apgar score, glycemia and serum bilirubin) were collected.
Moreover, a sample of colostrum (for NMR-based metabolomics, microbiota and high performance liquid chromatography-mass spectrometry -HPLC/MS- of vitamins analysis) and newborn faeces (for NMR-based metabolomics and microbiota analysis) sample will be collected.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Modena, Italy, 41124
- Recruiting
- Mother-Infant Department, University of Modena and Reggio Emilia, Italy
-
Sub-Investigator:
- Valeria Tamborrino, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged between 20 and 40 with singleton pregnancies and BMI at recruitment > 30 kg/m^2 or a BMI> 25 kg/m^2 and the simultaneous presence of at least 1 of the following risk factors: age> 35 years, previous fetal macrosomia (> 4500gr), family history of diabetes (first-degree relative with type 2 diabetes mellitus), previous gestational diabetes mellitus.
- Adherence to lifestyle prescription including dietary counselling and physical activity stimulation
Exclusion Criteria:
- Subjects who require intervention in addition to the lifestyle changes women with diet and habits much different from the Mediterranean area (Central Africa, Asian, etc..). In such subgroup it will be difficult to obtain adherence to diet prescription since their cultural attitudes and dietary habits.
- Pre-pregnancy BMI> 40 kg/m^2
- Chronic hypertension
- Fasting glycemia in the first trimester of> 126 mg / dl or random glycemia > 200 mg/dl
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
Placebo
|
The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
|
Experimental: Intervention
Probiotic VIVOMIXX™
|
The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal and newborn fecal microbiota changes (bifidobacteria and lactobacilli) and related enzymatic activity (alkaline sphingomyelinase and alkaline phosphatase) modifications
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
NMR-based metabolomics, microbiota and high performance liquid chromatography-mass spectrometry -HPLC/MS- of vitamins analysis
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Glucose metabolism changes
Time Frame: At 24-26 week
|
Positive Oral Glucose Tolerance Test
|
At 24-26 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight changes
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Measured in kg
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Maternal BMI
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Measured in kg/m^2
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Waist/hip circumference ratio
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
Gestational weight gain
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Measured in kg
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
HOMA Index
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
HbA1c1
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
glycemia
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
insulinemia
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
homocysteine plasmatic levels
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
|
Requirement for insulin therapy
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Week of onset
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Requirement for insulin therapy
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Dose of insulin
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Quality of sleep
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Hours of deep sleep measured through the armband
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Duration of sleep
Time Frame: At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Measured in hours through the armband
|
At baseline, at 24-26 week, at 36-38 week, 2-3 days after delivery
|
Onset of hypertension / preeclampsia
Time Frame: At delivery
|
At delivery
|
|
Time of delivery
Time Frame: At delivery
|
At delivery
|
|
Mode of delivery
Time Frame: At delivery
|
At delivery
|
|
Complications during delivery
Time Frame: At delivery
|
Surgery and/or hemorrhage >500ml and/or shoulder dystocia
|
At delivery
|
Apgar score
Time Frame: Within 1 hour after delivery
|
Within 1 hour after delivery
|
|
Newborn's weight
Time Frame: Within 1 hour after delivery
|
Within 1 hour after delivery
|
|
Newborn's sex
Time Frame: Within 1 hour after delivery
|
Within 1 hour after delivery
|
|
Newborn's abdomen / head ratio
Time Frame: 2-3 days after delivery
|
2-3 days after delivery
|
|
Newborn's skinfold thickness at birth
Time Frame: 2-3 days after delivery
|
2-3 days after delivery
|
|
Neonatal hypoglycemia
Time Frame: Within 24 hours from delivery
|
Neonatal hypoglycemia (measured in mg/dl) that requires therapy
|
Within 24 hours from delivery
|
Neonatal bilirubinemia
Time Frame: At delivery, 2-3 days after delivery
|
Measured in mg/dl
|
At delivery, 2-3 days after delivery
|
Neonatal complications
Time Frame: 2-3 days after delivery
|
Respiratory Distress Syndrome, Necrotizing Enterocolitis, Retinopathy of prematurity, Bronchopulmonary Dysplasia, Neonatal Death
|
2-3 days after delivery
|
Admission to Neonatal Intensive Care Unit (NICU)
Time Frame: Within 24 hours after delivery
|
Admission to NICU
|
Within 24 hours after delivery
|
Admission to Neonatal Intensive Care Unit (NICU)
Time Frame: Within 24 hours after delivery
|
Duration of stay at the NICU
|
Within 24 hours after delivery
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CE 91/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise Addiction
-
University Hospital, CaenINSERM UMR U1075 Comète GIP Cyceron, unicaen, Caen NormandieRecruiting
-
Universidade Estadual do Centro-OesteCompleted
-
Xueqing ZhangCompletedExercise | Randomized Clinical Trial | Internet Addiction | Tai ChiChina
-
Okan UniversityCompletedExercise Addiction | Upper Extremity | Wrestling | Trunk Muscle StrengthTurkey
-
TCI Co., Ltd.Completed
-
Universidad Europea de MadridCompleted
-
Reyhan KaygusuzTerminatedHeart Diseases | Exercise Addiction | SensitivityTurkey
-
Eastern Mediterranean UniversityHacettepe UniversityActive, not recruitingChronic Neck Pain | Exercise AddictionCyprus
-
Universidade Luterana do BrasilCompletedOsteoarthritis, Knee | Exercise Addiction | Self Stimulation
-
Hasan Kalyoncu UniversityRecruiting
Clinical Trials on Probiotic VIVOMIXX™
-
Singapore General HospitalUnknownSystemic SclerosisSingapore
-
Universitätsklinikum Hamburg-EppendorfCompletedStress | Anxiety | Depressive SymptomsGermany
-
Centre Hospitalier Universitaire de BesanconRecruitingChronic Renal Failure | Systemic Inflammation | Diabete Type 2France
-
University of MilanRecruiting
-
Centre Hospitalier Universitaire de NiceRecruitingNeurocognitive Disorders | HIVFrance
-
Lund UniversityCompleted
-
University of Roma La SapienzaUnknownHIV | Anal DysplasiaItaly
-
Xijing Hospital of Digestive DiseasesMENDES SAUnknown
-
Changi General HospitalRecruiting